SCHEMBL14825362

SCHEMBL14825362

CCOC(=O)c1ccnc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 6/20 0.48
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ KCNH2 Q12809 5/20 0.45
▸ ACHE P22303 2/20 0.44
▸ PIK3CA P42336 1/20 0.43
▸ JMJD6 Q6NYC1 1/20 0.43
▸ HRH1 P35367 2/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825424 0.96 OPRD1 (0.55) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825403 0.90 OPRD1 (0.58) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825488 0.89 OPRD1 (0.46) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825515 0.89 OPRD1 (0.51) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825838 0.87 OPRD1 (0.55) OPRD1MEN1KMT2AKCNH2HRH1
SCHEMBL14825842 0.86 OPRD1 (0.54) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825365 0.85 KDM4C (0.58) OPRD1MEN1KMT2AATMACHE
SCHEMBL14825534 0.85 OPRD1 (0.49) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825504 0.84 OPRD1 (0.46) OPRD1MEN1KMT2AATMKCNH2
SCHEMBL14825474 0.83 CACNA2D1 (0.52) OPRD1MEN1KMT2AATMKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 OPRD1 129/4885MEN1 2318/4885KMT2A 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback